FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Penicillamine Tablets 250 mg Recall

Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Ph…

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Dec 20, 2023
Recall ID
D-0148-2024
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Penicillamine Tablets 250 mg starting Nov 22, 2023. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0148-2024 on Dec 20, 2023. Reason: Failed Dissolution Specifications. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications

Product description

Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Lupin Limited, Nagpur-441 108, India, NDC# 70748-153-01

Lot numbers, UPCs & expiration codes

Lot # M200498, Exp. June 2024

Where it was sold

Product was distributed to 3 wholesale/distributor accounts.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0148-2024
Classification
Class II
Status
Terminated
Recall initiated
Nov 22, 2023
FDA report date
Dec 20, 2023
Quantity
N/A
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0148-2024, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
93482
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
Lot # M200498, Exp. June 2024
Postal code
21202-6174
Report date
Dec 20, 2023
Product type
Drugs
Recall number
D-0148-2024
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Termination date
Jul 8, 2024
Reason for recall
Failed Dissolution Specifications
Voluntary / mandated
Voluntary: Firm initiated
Product description
Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Lupin Limited, Nagpur-441 108, India, NDC# 70748-153-01
Distribution pattern
Product was distributed to 3 wholesale/distributor accounts.
Recall initiation date
Nov 22, 2023
Initial firm notification
Letter
Center classification date
Dec 13, 2023

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0148-2024, published Dec 20, 2023. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls